(Q36292899)

English

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Jassem J

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Bontenbal M

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Andersson M

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Wildiers J

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Cocconi G

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Paridaens R

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Rotmensz N

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sylvester R

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Mouridsen HT

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Klijn JG

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

van Oosterom AT

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

1 June 1998

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

77

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

2257-2263

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1998.375

0 references

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

A phase of I trial of 4'-epi-Adriamycin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

New cytotoxic drugs in treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

30 September 2017

Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

29 June 2018

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

29 June 2018

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

29 June 2018

Anthracycline derivatives in new drug development programs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

29 June 2018

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

22 September 2018

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150384

22 September 2018

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxic and therapeutic activity of 4'-epi-doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of doxorubicin versus epirubicin in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer]

1 reference

https://pubmed.ncbi.nlm.nih.gov/9649142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1998.375

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36292899&oldid=1956440620"